C4 Therapeutics Inc
Research C4 Therapeutics Inc (CCCC) on Bullrun: market cap USD 464.38M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCCCC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 464.38M
- Financial periodQ1 2026
- RevenueUSD 6.15M
- Net income-USD 103.80M
- Free cash flow-USD 96.02M
Valuation Snapshot
latest market cap is USD 464.38M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 35.95M | -USD 104.99M | -USD 99.30M | n/a | -1.27 | USD 74.60M | USD 59.98M | USD 256.59M |
| FY2024 | USD 35.58M | -USD 105.32M | -USD 65.34M | n/a | -1.52 | USD 55.50M | USD 65.76M | USD 215.99M |
| FY2023 | USD 20.76M | -USD 132.49M | -USD 108.55M | n/a | -2.67 | USD 126.59M | USD 0 | USD 246.11M |
| FY2022 | USD 31.10M | -USD 128.18M | -USD 111.44M | n/a | -2.62 | USD 29.75M | USD 11.48M | USD 289.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 464.38M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 185.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 254.25M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 278.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 288.85M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.57B | n/a | n/a | n/a |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is C4 Therapeutics Inc's market cap?
C4 Therapeutics Inc's market capitalization is USD 464.38M.
What does C4 Therapeutics Inc do?
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.